Inhibrx Biosciences' cash runway is tight, with $261.7M cash, $275M debt, and further financing options uncertain. Learn why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results